Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Deferred Revenue (2016 - 2023)

Fortress Biotech has reported Current Deferred Revenue over the past 6 years, most recently at $547000.0 for Q1 2023.

  • Quarterly results put Current Deferred Revenue at $547000.0 for Q1 2023, down 73.11% from a year ago — trailing twelve months through Mar 2023 was $547000.0 (down 73.11% YoY), and the annual figure for FY2022 was $728000.0, down 72.12%.
  • Current Deferred Revenue for Q1 2023 was $547000.0 at Fortress Biotech, down from $728000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for FBIO hit a ceiling of $7.2 million in Q1 2021 and a floor of $547000.0 in Q1 2023.
  • Median Current Deferred Revenue over the past 3 years was $2.0 million (2022), compared with a mean of $2.6 million.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 67.41% in 2022 and later plummeted 73.11% in 2023.
  • Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then crashed by 72.12% to $728000.0 in 2022, then decreased by 24.86% to $547000.0 in 2023.
  • The last three reported values for Current Deferred Revenue were $547000.0 (Q1 2023), $728000.0 (Q4 2022), and $1.1 million (Q3 2022) per Business Quant data.